06 Affective Disorders Flashcards
dysthymia vs. hyperthymia
- dysthymia: prolonged grief / love sickness
- hyperthymia: in love / ecstasy
depressive episode, manic episode, bipolar disorder
- depressive episode: depressed for more than 2 weeks
- manic episode: abnormally elevated mood for more than 1 week
- bipolar disorder: depressive episode + at least 1 (hypomanic) episode
prevalence of affective disorders in Europe
- depression: 6,9% (30,3 mio.)
- bipolar disorder: 0,9% (3,0 mio.)
outdated triadic system for mental disorders
- somatically caused mental syndroms (exogene Psychose)
- mental disease (endogene Psychose) (assumed somatic etiology)
- mental disorder
primary vs. secondary disorder
- primary disorder: no apparent somatic cause (e.g. bipolar disorder, MDD)
- secondary disorder: somatic cause (e.g. premenstrual dysphoric disorder, substance-induced mood disorder)
- for all primary disorders, there are also secondary types
treatment strategies for mood disorders
not severe
- lifestyle treatments (e.g. exercise, diet, sleep, activity, stress reduction)
- social treatments (e.g. family, psychoeducation, housing)
- psychological treatments (e.g. CBT, mindfulness)
- biological treatments (e.g. antidepressants, antipsychotics, mood stabilizers, ECT, TMS, new: Esketamin)
severe
symptoms of depression
3 core symptoms:
- decreased mood
- decreased drive & energy
- anhedonia (reduced interest and pleasure)
other symptoms:
- appetite, negative and pessimistic thoughts about the future (rumination), sleeping problems, low self-worth and self-confidence, feelings of guilt and worthlessness, impaired cognition, suicidality
severity of depression
symptoms at least two weeks for most of the time
- mild: 2 core symptoms, 2 additional symptoms
- moderate: 2 core symptoms, 3-4 additional symptoms
- severe: 3 core symptoms, 4 or more additional symptoms
diagnostic criteria for depressive episode
at least 5 out of 9 symptoms - including either 1 or 2 - for at least 2 weeks
- depressed mood
- markedly diminished interest or pleasure in (almost) all activities
- weight loss or decrease or increase in appetite
- insomnia or hypersomnia
- psychomotor agitation or retardation
- fatigue or loss of energy
- feelings of worthlessness or excessive or inappropriate guilt
- diminished ability to think or concentrate, or indecisiveness
- recurrent thoughts of death, recurrent suicidal ideation, or specific suicide plan or suicide attempt
- hopelessness
best predictor for depression
hopelessness
frequency of somatic symptoms (pain in particular)
2/3 of all patients
depression - course of illness
- often episodic (33%), can be recurrent (36%) or even chronic (32%)
- impairment/disability persists often beyond depressive episode
- 50% of major depressive episodes remit within 3 months
- severe and comorbid depression average duration: 7,6 months
- the longer the episode, the lower the probability of remission
MDD - epidemiology
- 1-year prevalence: 6.9%, 30.3 mio.
- 20% of German citiziens suffer from at least 1 MDD episode in life: 25% of women, 10% of men, 5% under 20, 2% under 12
- only half of all patients are diagnosed
- only half of diagnosed patients receive therapy (75% untreated)
- 50% or worldwide suicides during depressive episode
- 15% of all former inpatients with recurrent MDD commit suicide
further clinical symptoms
- epiosde duration: 8-16 weeks, 6 months in the past
- irritability and anger frequent in males, children, adolescent, early warning sign for relapse
- cognitive dysfunction frequent (pseudodementia)
- psychiatric comorbidity with anxiety, also addiction and others
- non-psychiatric comorbidity like DM II, obesity, hypertension, arteriosclerosis, immunological disorders
- only 50% of patients respond to first treatment
- 30% turn from episodic to chronic = persistent depressive disorder (> 2 years)
recent developments in depression therapy
- Ketamin: either intravenous (not-approved, cheap) or nasal (approved, costly)
- psychedelic supported psychotherapy: psylocibin
- intensive TMS: 6-8 times per day for 1 week
- deep brain stimulation: high hopes, but evidence not really promising